Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)

Both doses of deuruxolitinib were effective for hair regrowth. Patient satisfaction aligned with hair growth.